Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages HUTCHMED (China) Limited Nasdaq

Equities

HCM

US44842L1035

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
19.4 USD +9.11% Intraday chart for HUTCHMED (China) Limited +5.09% +7.12%
Jul. 09 Transcript : HUTCHMED Limited - Special Call
Jul. 05 Sector Update: Health Care Stocks Advance Late Afternoon MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Advance Late Afternoon
Hutchmed's tazemetostat given priority review in China
Sector Update: Health Care Stocks Advance in Afternoon Trading
Hutchmed Shares Rise After Tazemetostat Gets Priority Review Status in China
Hutchmed's NDA for Lymphoma Drug Gets Priority Review Status in China
HUTCHMED Limited Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review
Takeda's Cancer Drug Gets European Commission Approval
Hutchmed China notes Takeda obtains EU approval for Fruzaqla
Hutchmed celebrates "promising" results for sovleplenib in China
Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology
Hutchmed (China) begins trial of menin inhibitor HMPL-506
Hutchmed (China)'a Cancer Drug Phase I Clinical Trial Begins
HUTCHMED Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
HUTCHMED Limited Announces Results from FRUTIGA, HUTCHMED's Phase III Trial of Fruquintinib in Combination with Paclitaxel for the Treatment of Second-Line Advanced Gastric Cancer
HUTCHMED Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology
Hutchmed (China) Chairman Resigns, Successor Named
Hutchmed China Simon To leaves role, succeeded by Dan Eldar
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor
HUTCHMED Limited Announces Executive Changes
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HCM Stock
  4. HCM Stock
  5. News HUTCHMED (China) Limited
  6. Other languages